Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SY-005 in Healthy Subjects
NCT04217629Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of annexin a5 in sepsis (9 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Incidence of adverse events of SY-005 at 28 days. Started Apr 2019; status: completed.
02
Drugs
annexin a5
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT04217629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217629.